PSMA-Targeted Mesoporous Silica Nanoparticles for Selective Intracellular Delivery of Docetaxel in Prostate Cancer Cells
Open Access
- 15 January 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 4 (1) , 1281-1291
Abstract
Although docetaxel is currently broadly used in prostate cancer treatment, poor water solubility and systemic toxicity limit the dose and duration of therapy. In this context, although different nanoplatforms have been proposed to overcome these issues, selective therapy needs developing methodologies to target malignant cells and minimizing the impact on healthy tissue. We here present a novel drug delivery system obtained by covalent conjugation of docetaxel and an anti-prostate specific membrane antigen (PSMA) molecule (anti-FOLH1 monoclonal antibody, clone C803N) over mesoporous silica nanoparticles. This conjugate remains stable in physiological medium and shows high selectivity for LNCaP, a specific cell line that overexpresses PSMA. As a consequence, cell internalization is increased by 25%. Furthermore, cytotoxic activity of the targeted system increases by 2-fold with regard to nontargeted nanoparticles and by 2 orders with regard to the naked drug. Conversely, no targeting effect is observed over PC3, a nonbearing PSMA cell line. We expect that this therapeutic system shows strong potential for treating nonmetastatic prostate cancer, mostly through intraprostatic administration.Keywords
Funding Information
- Generalitat Valenciana (PROMETEO/2017/060)
- Secretaría de Estado de Investigación, Desarrollo e Innovación (TEC2016-80976-R, MAT2015-66666-C3-2-R, SEV-2016-0683)
This publication has 61 references indexed in Scilit:
- Benefit risk assessment and update on the use of docetaxel in the management of breast cancerCancer Management and Research, 2013
- Magnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell deathInternational Journal of Nanomedicine, 2013
- Synthesis, characterization and antitumor evaluation of CMCS–DTX conjugates as novel delivery platform for docetaxelInternational Journal of Pharmaceutics, 2013
- Measurement of Uptake and Release Capacities of Mesoporous Silica Nanoparticles Enabled by Nanovalve GatesThe Journal of Physical Chemistry C, 2011
- Prostate cancer targeting motifs: Expression of ανβ3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenograftsThe Prostate, 2011
- Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanismsNanomedicine: Nanotechnology, Biology and Medicine, 2011
- Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer CellsNanoBiotechnology, 2007
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences, 2006
- Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patientsInternational Journal of Cancer, 2003
- Docetaxel in non-small cell lung cancer: a reviewExpert Opinion on Pharmacotherapy, 2003